On November 9, Palantir rose 3.17% in Regular Trading, trading at $164.735 per share, with turnover of $331 million.

The move aligns with recent event-driven developments: the UK plans to extend Palantir's NHS contract while preparing potential alternatives, and the company also said it will expand AI capabilities across AmeriLife workflows in the coming months.

Recent background was supportive. Earlier reports said Palantir rose after the NHS-related update and the AmeriLife expansion plan, reinforcing attention on both its government and commercial AI rollout. That followed strong quarterly results released on November 2, when revenue reached $2.313 billion, up 96% year over year, with US commercial revenue of $984 million exceeding US government revenue of $953 million, alongside raised full-year revenue guidance to about $8.53 billion. Separately, several brokers lifted price targets in recent days, including levels of $233, $235, $250, $265 and $273, underscoring continued bullish long-term expectations despite mixed options positioning and short-term valuation pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)